(especial para SIIC © Derechos reservados)

Autores comunican

Rio de Janeiro, Brasil (especial para SIIC):
Nós demonstramos anteriormente que a administração oral de um antígeno particulado de Leishmania amazonensis promotor de doença (LaAg) parcialmente protege camundongos contra a leishmaniose cutânea. Neste trabalho, nós procuramos otimizar a vacina de mucosa usando a via intranasal para a administração de diferentes antígenos, incluindo o antígeno bruto LaAg, uma proteina recombinante de leishmania (LACK) e DNA codificando LACK (LACK DNA). Camundongos BALB/c pré-vacinados com duas doses de 10 microgramas de LaAg desenvolveram um controle tardio mas efetivo contra a doença. A diminuição da carga parasitária foi acompanhada de aumento da produção tanto de IFN-gama como de IL-10 nos linfonodos drenantes da lesão. A eficácia da vacina foi de longa duração, sendo ainda mais eficaz após 4 meses que após 1 semana da administração. Ao contrário da vacina bruta, a vacina recombinante administrada sem adjuvantes não foi eficaz pela via intranasal. Por outro lado, o LACK DNA (30 microgramas /dose) promoveu uma imunidade protetora rápida e duradoura. Após a infecção, o crescimento dos parasitos foi irrisório, e 5 meses depois células reativas ao LACK tanto nos linfonodos que drenavam a mucosa nasal como os que drenavam a lesão produziam altos níveis de interferon-gama. Estes resultados demonstraram pela primeira vez a possibilidade de se usar a via intranasal para induzir uma imunidade de longa duração contra a leishmaniose cutânea com antígeno bruto ou DNA na ausência de adjuvantes.

Bartira Rossi Bergmann *

Referencias bibliográficas

1. Bakke H, Lie K, IL Haugen, GE Korsvold, EA Høiby, LM Næss, JHolst, IS Aaberge, F Oftung and B Haneberg. 2001. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect. Immun. 69:5010–5015.
2. Barnes AGC, C Barnfield, R Brew and LS Klavinskis. 2000. Recent developments in mucosal delivery of pDNA vaccines. Curr. Opin. Molec. Therap. 2:87-93.
3. Belkaid Y. 2003. The role of CD4+CD25+ regulatory T cells in Leishmania infection. Expert Opin. Biol.Ther. 3:875-885.
4. Campbell M, H Diao, JX Ji and L Soong. 2003. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect. Immun. 71:6270-6278.
5. Chen LH, J Wang, A Zganiacz and Z Xing. 2004. Single intranasal mucosal Mycobactetium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72:238-246.
6. Croft SL and GH Coombs. 2003. Leishmaniasis- current chemotherapy and recent advances in the search for novel drugs. Trends in Parasitol. 19:502-508.
7. Czerkinsky C, FAnjuere, JR McGhee, A George-Chandy, J Holmgren, M Kieny, K Fujiyashi, JF Mestecky, V Pierrefite-Carle, C Rask and J Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170:197-222.
8. Dhaliwal JS and FY Liew. 1987. Induction of delayed-type hypersensitivity to Leishmania major and the concomitant acceleration of disease development in progressive murine cutaneous leishmaniasis. Infect. Immun. 55:645-651.
9. Dumonteil E, RSM Jesus, EO Javier and GMM del Rosario. 2003. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 21:2161-2168.
10. Fujihashi K, T Koga, FW van Ginkel, Y Hagiwara and JR McGhee. 2002. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine; 20:2431-2438.
11. Gonzalez-Aseguinolaza G, S Taladriz, A Marquet and V Larraga. 1999. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. Eur. J. Biochem. 259:909-916.
12. Gurunathan S, DL Sacks, DR Brown, SL Reiner, H Charest, N Glaichenhaus and RA Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-47.
13. Hamann A, DP Andrew, D Jablonskiwestrich, B Holzmann and EC Butcher. 1994. Role of alpha (4)-integrins in lymphocyte homing to mucosal tissues in-vivo. J. Immunol. 152:3282-3293.
14. Handman E. 2001. Leishmaniasis: Current status of vaccine development. Clin. Microbiol. Rev. 14:229–243.
15. Jones DE, MR Ackermann, U Wille, CA Hunter and Scott P. 2002. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect. Immun. 70:2151-2158.
16. Julia V, M Rassoulzadegan and N Glaichenhaus. 1996. Resistance to Leishmania major induced by tolerance to a single antigen. Science 274:421-423.
17. Julia V, SS McSorley, L Malherbe, JP Breittmayer, F Girard-Pipau, A Beck and N Glaichenhaus. 2000. Priming by microbial antigens from the intestinal flora determines the ability of CD4(+) T cells to rapidly secrete IL-4 in BALB/c mice infected with Leishmania major. J. Immunol. 165:5637-5645.
18. Kaiserlian D and N Etchart. 1999. Entry sites for oral vaccines and drugs: A role for M cells, enterocytes and dendritic cells? Semin Immunol. 11:217-24.
19. Kenney RT, DL Sacks, JP Sypek, L Vilela, AA Gam and K Evans-Davis. 1999. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163:4481-4488.
20. Launois P, I Maillard, S Pingel, KG Swihart, I Xenarios, H Acha-Orbea, H Diggelmann, RM Locksley, HR MacDonald and JA Louis. 1997. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6:541-549.
21. Liew FY, C Hale and JG Howard. 1985. Prophylactic immunization against experimental leishmaniasis. IV.Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J. Immunol. 135:2095-2101.
22. Lira R, S Sundar, A Makharia, R Kenney, A Gam, E Saraiva and D Sacks. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180:564-567.
23. Makala LHC, Y Nishikawa, N Suzuki and H Nagasawa. 2004. Immunology - Antigen-presenting cells in the gut. J. Biomed. Sci. 11:130-141.
24. Marzochi KBF, MCA Marzochi, AF Silva, N Grativol, R Duarte, EM Conort and F Modabber. 1998. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil. Mem Inst Oswaldo Cruz 93:205-212.
25. McCluskie MJ and HL Davis. 1998 CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 161:4463-6.
26. McSorley SJ, C Rask, R Pichot, V Julia, C Czerkinsky and N Glaichenhaus. 1998. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur. J. Immunol. 28:424-432.
27. Melby PC, J Yang, W Zhao, LE Perez and J Cheng. 2001. Leishmania donovani p36(LACK) DNA Vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
28. Mendez A, Y Belkaid, RA Seder and D Sacks. 2002. Optimisation of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702-3708.
29. Mosmann TR and S Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138-146.
30. Oh YK, JP Kim, TS Hwang, JJ Ko, JM Kim, JS Yang and CK Kim. 2001. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine 19:4519-4525.
31. Okuno T, M Takeuchi, Y Matsumoto, H Otsuka and Y Matsumoto. 2002. Pretreatment of Leishmania homologue of receptors for activated C kinase (LACK) promotes disease progression caused by Leishmania amazonensis. Exp. Animals 51:335-341.
32. Pinto EF, MM Cortezia and B Rossi-Bergmann. 2003. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis. Vaccine 21:3534-3541.
33. Pompeu MML, C Brodskyn, MJ Teixeira, J Clarencio, J Van Weyenberg, ICB Coelho, SA Cardoso, A Barral, M Barral-Netto. 2001. Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers. Infec. Immun. 69:7453-7460.
34. Ramiro MJ, JJ Zarate, T Hanke, D Rodriguez, JR Rodriguez, M Esteban, J Lucientes, JA Castillo and V Larraga. 2003. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21:2474-84.
35. Reiner SL and RM Locksley. 1995. The regulation of immunity to Leishmania major. Ann. Rev. Immunol. 13:151-177.
36. Rossi-Bergmann B, A Lenglet, CR Bezerra-Santos, D Costa-Pinto and YM Traub-Czeko. 1999. Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo. Mem. I. Oswaldo Cruz 94 (Suppl. II):74.
37. Shah JA, PA Darrah, DR Ambrozak, TN Turon, S Mendez, J Kirman, CY Wu, N Glaichenhaus and RA Seder. 2003. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J. Exp. Med. 198:281-291.
38. World Health Organization/TDR. Tropical Diseases Research - Leishmaniasis. Fourteen Programme Report. 1999:22.
39. Xu D and FY Liew. 1994. Genetic vaccination against leishmaniasis. Vaccine 12:1534-1536.

Intranasal Vaccination against Cutaneous Leishmaniasis with a Particulated Leishmanial Antigen or DNA Encoding LACK

Título en portugués
VACINAÇÃO INTRANASAL CONTRA A LEISHMANIOSE CUTÂNEA COM UM ANTÍGENO PARTICULADO DE LEISHMANIA OU COM DNA CODIFICANDO LACK

Autora
Bartira Rossi Bergmann

Clasificado en siicsalud